Supplementary Table S2 from Targeting SALL4 with an HLA Class I–Restricted TCR for Cancer Immunotherapy

Myriam Ben Khelil; Maxime Fredon; Nawfel Adib; Adeline Bouard; Marie Perchaud; Syrine Abdeljaoued; Charles-Frédéric Mantion; Kamal Asgarov; Philippe Guillaume; Laurie Spehner; Evan Seffar; Marjorie Labesse; Angélique Vienot; Virginie Mougey; Mathieu Gonçalves-Venturelli; Sara Bobisse; Alexandre Harari; Camilla Jandus; Francine Garnache‐Ottou; Delphine Binda; Olivier Adotévi; Yann Godet; Marie Kroemer; Christophe Borg; Romain Loyon

doi:10.1158/2326-6066.31024172

Supplementary Table S2 from Targeting SALL4 with an HLA Class I–Restricted TCR for Cancer Immunotherapy

2026 Open access

Read full text

Authors: Myriam Ben Khelil, Maxime Fredon, Nawfel Adib, Adeline Bouard, Marie Perchaud, Syrine Abdeljaoued, Charles-Frédéric Mantion, Kamal Asgarov, Philippe Guillaume, Laurie Spehner, Evan Seffar, Marjorie Labesse

+13 more

Angélique Vienot, Virginie Mougey, Mathieu Gonçalves-Venturelli, Sara Bobisse, Alexandre Harari, Camilla Jandus, Francine Garnache‐Ottou, Delphine Binda, Olivier Adotévi, Yann Godet, Marie Kroemer, Christophe Borg, Romain Loyon

DOI: 10.1158/2326-6066.31024172

Cited by: 0

Abstract

Supplementary Table S2: List of antibodies and flow cytometry regents used

Fields of Study & Subjects

Renal and related cancers CAR-T cell therapy research Acute Lymphoblastic Leukemia research

Publication details

Publication date: 8 January 2026